TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: SHILPAMED · data 2026-11-02
Shilpa Medicare Limited
In plain words
Price: 14.6% below its 52-week high of ₹1,095.
Delivery: 41.9% of traded shares were kept for delivery over the last 10 sessions, against 40.4% over the last 60.
Latest results: a net profit of ₹101 cr for the quarter ended Jun 2026 (+115.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,682 cr |
| Net profit (last 12 months) | ₹297 cr |
| Sales growth, 3 years (yearly) | 13.8% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 40.1% (-4.1 pts in a year), pledged 4.9%, institutions 20.4%.
P/E 61.5, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 9.8%, ROCE 9.0%, operating margin 21.0%: how much profit it earns on the money it uses.
Debt/equity 0.25, Profit growth — and sales growth 13.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (21.0%).
- Promoters have pledged 4.9% of their shares.
- Promoters cut their holding by 4.1 points in a year.
- Expensive on earnings (P/E 61.5).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
SHILPAMED Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹465.78 crore, up 44.9% YoY and up 6.6% QoQ.
Net profit was ₹100.88 crore, up 115.1% YoY and down 6.4% QoQ.
Operating margin was 29.3% (28.5% a year ago).
EPS was ₹5.16, up 115% YoY and down 6.4% QoQ.
SHILPAMED के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹465.78 करोड़; पिछले साल की तुलना में 44.9% की बढ़त, पिछली तिमाही की तुलना में 6.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹100.88 करोड़; पिछले साल की तुलना में 115.1% की बढ़त, पिछली तिमाही की तुलना में 6.4% की गिरावट।
ऑपरेटिंग मार्जिन: 29.3% (एक साल पहले 28.5%)।
EPS: ₹5.16; पिछले साल की तुलना में 115% की बढ़त, पिछली तिमाही की तुलना में 6.4% की गिरावट।
SHILPAMEDના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹465.78 કરોડ; ગયા વર્ષની સરખામણીએ 44.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.6% વધારો.
ચોખ્ખો નફો: ₹100.88 કરોડ; ગયા વર્ષની સરખામણીએ 115.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.4% ઘટાડો.
ઓપરેટિંગ માર્જિન: 29.3% (એક વર્ષ પહેલાં 28.5%).
EPS: ₹5.16; ગયા વર્ષની સરખામણીએ 115% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.4% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 44.5% over the last 20 sessions vs 25.7% in the 40 before (1.73x); shares delivered per day 0.67x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results ● Bonus
- 4 Sept 26Dividend Dividend ₹0.6 (ex-date) -1.7% next session
- 5 Aug 26Results Q1 FY27 results: profit +115.1% YoY +14.6% next session
- 22 May 26Results Q4 FY26 results: profit +642.9% YoY +7.9% next session
- 6 Feb 26Results Q3 FY26 results: profit +40.3% YoY +5.3% next session
- 13 Nov 25Results Q2 FY26 results: profit +145.7% YoY -5.1% next session
- 3 Oct 25Bonus Bonus 1:1 (ex-date)
- 17 Sept 25Dividend Dividend ₹1 (ex-date) -1.1% next session
- 13 Aug 25Results Q1 FY26 results: profit +233.5% YoY +4.4% next session
- 26 May 25Results Q4 FY25 results: profit −40.8% YoY +11.6% next session
- 11 Feb 25Results Q3 FY25 results: profit +559.3% YoY -4.4% next session
- 14 Nov 24Results Q2 FY25 results: profit +1064.9% YoY +4.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹466 cr | ₹101 cr | +115.1% | 29.3% | 5.16 |
| Mar 2026 | ₹437 cr | ₹108 cr | +642.9% | 27.4% | 5.51 |
| Dec 2025 | ₹410 cr | ₹45 cr | +40.3% | 27.9% | 2.36 |
| Sept 2025 | ₹370 cr | ₹44 cr | +145.7% | 29.3% | 2.25 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 40.13% | 40.13% | 40.13% | 40.13% |
| Foreign institutions (FII) | 12.11% | 11.38% | 11.08% | 10.97% |
| Domestic institutions (DII) | 8.26% | 8.05% | 8.58% | 8.33% |
| Mutual funds | 4.20% | 4.21% | 5.15% | 5.20% |
| Retail investors | 16.86% | 16.44% | 15.32% | 15.03% |
| Number of shareholders | 87,477 | 60,926 | 53,410 | 53,799 |
Common questions
What was Shilpa Medicare Limited's latest quarterly profit?
Shilpa Medicare Limited reported a net profit of ₹101 cr for the quarter ended Jun 2026 (+115.1% on the same quarter a year earlier), on revenue of ₹466 cr.
How much do promoters hold in Shilpa Medicare Limited?
Promoters held 40.13% of Shilpa Medicare Limited at the end of Sept 2026, with 4.90% of promoter shares pledged.
Is Shilpa Medicare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.25.
What is Shilpa Medicare Limited's P/E ratio?
About 61.5, based on the last 12 months' earnings and a price of ₹935 (data 2026-11-02).
What is the 52-week high and low of Shilpa Medicare Limited?
The 52-week high is ₹1,095 and the 52-week low is ₹259.5.
Mutual funds holding Shilpa Medicare Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹107 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.95% | ₹58 cr |
| ADITYA BIRLA SUN LIFE MANUFACTURING EQUITY FUND | Aditya Birla Sun Life Mutual Fund | 2.38% | ₹33 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.43% | ₹15 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Shilpa Medicare Limited | ₹935 | ₹18,671 cr | 61.5 | — | 9.8% | 9% | 0.25 | +159.7% |
| OneSource Specialty Pharma Limited | ₹1,583.1 | ₹17,926 cr | — | 3.1 | -1.3% | -0.1% | 0.26 | -14.4% |
| Caplin Point Laboratories Limited | ₹2,326.2 | ₹17,672 cr | 26.7 | — | 19.9% | 20.9% | 0 | +14.3% |
| Alivus Life Sciences Ltd | ₹1,447.5 | ₹17,284 cr | 26.6 | 4.9 | 18.4% | 22.4% | 0.02 | +59.4% |
| Cohance Lifesciences Ltd | ₹445.7 | ₹17,005 cr | 161.5 | 4.4 | 6.4% | 4.6% | 0.1 | -42.8% |
| PFIZER LIMITED | ₹3,630.6 | ₹16,867 cr | 22.6 | — | 17.2% | 20% | 0.02 | -31.8% |
Compare SHILPAMED with ONESOURCE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SHILPAMED in TickerKhoj →